Identifying innovative ideas to turn them into new business opportunities
Actelion has a dedicated team focused on identifying innovation from external sources that complements our business approach. Once identified, Actelion is rapid, proactive and open in creating benefits for both parties. We commit ourselves to the project we share with our partner, to make the product a global success.
Actelion / Trophos collaboration
Actelion and Trophos entered into a binding agreement in July 2010 whereby Actelion obtained an exclusive option to acquire privately-held Trophos SA, a clinical stage pharmaceutical company. Trophos' lead compound olesoxime is investigated in a Phase III study in Amyotrophic Lateral Sclerosis (ALS), an orphan disease also known as Lou Gehrig's disease. This study is expected to report data by the end of 2011; at this time Actelion may exercise the option to acquire Trophos.
Actelion / Nippon Shinyaku alliance
Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in April 2008 to collaborate on an orally-available long-acting prostaglandin I2 (PGI2) receptor agonist for patients suffering from pulmonary arterial hypertension (PAH). This compound was originally discovered and synthesized by Nippon Shinyaku. Phase I evaluation has recently been completed, and a Phase II program in PAH patients was initiated by Nippon Shinyaku in Europe at the end of 2007. Actelion will be responsible for global development and commercialization of the PGI2 receptor agonist outside Japan, while the two companies will co-develop and co- ommercialize in Japan.
Actelion / Bayer Schering Pharma AG alliance
Actelion holds the exclusive US rights for inhaled iloprost, marketed under the brand name Ventavis®, the only approved inhaled treatment for pulmonary arterial hypertension (PAH), licensed from Bayer Schering Pharma AG (through the acquisition of CoTherix Inc.). Actelion has the US development responsibilities, and has established a joint Development and Commercialization Committee for future collaboration with Bayer Schering Pharma AG. Actelion books all sales of Ventavis® in the US, and pays a royalty on sales to Bayer Schering Pharma AG. In addition to this royalty, Actelion is contractually required to pay one final milestone payment to Bayer Schering Pharma AG upon achieving a set sales target.
Actelion / Oxford GlycoSciences alliance
In November 2002, Actelion in-licensed miglustat, the active ingredient of Zavesca®, from Oxford GlycoSciences (UK) Ltd. Zavesca came to the market in the European Union in March 2003, followed by the United States in January 2004. In November 2005, Actelion entered an agreement with UCB S.A., the legal successor to Oxford GlycoSciences under wich UCB S.A. assigned all rights and obligations regarding miglustat, including worldwide marketing rights, to Actelion (except in Israel, the West Bank and the Gaza Strip).
